Pregnancy RSV shots: what the newest CDC data say about uptake, timing, and safety
CDC’s latest coverage dashboard shows that many pregnant people still have not chosen an RSV prevention strategy. The practical question is still timing: maternal Abrysvo in late pregnancy or infant nirsevimab after birth.
The newest CDC data suggest there is still room to close the gap on RSV protection in pregnancy. For families, the main decision is still about timing: whether maternal RSV vaccination in late pregnancy makes sense, or whether the baby should receive an RSV antibody after birth.
That choice depends on gestational age, where you are in the RSV season, and when the baby is expected to arrive. It is not a one-size-fits-all decision, and CDC says pregnant people and their clinicians should discuss both options.
What CDC recommends
CDC recommends a single dose of Pfizer’s Abrysvo during weeks 32 through 36 of pregnancy, generally from September through January in most of the continental United States. The goal is to pass protection to the baby before birth so the infant has protection during the first RSV season.
CDC also says most infants will not need both strategies. If maternal vaccination did not happen, or happened too late in pregnancy to be useful, the baby should receive nirsevimab just before or at the start of the RSV season, or shortly after birth when indicated.
What the coverage dashboard adds
CDC’s pregnant-women coverage dashboard shows that uptake is still incomplete. In plain terms, that means many families have not yet been protected by either maternal vaccination or an infant antibody strategy.
The dashboard uses electronic health record data from the Vaccine Safety Datalink and was updated March 11, 2026. CDC notes that weekly estimates may undercount coverage and can change as the season progresses. That makes the numbers useful for context, but not a final season total.
That matters because RSV is still a major cause of hospital care in infants, especially in the first months of life. Real-world studies published over the past year suggest both maternal vaccination and nirsevimab can help reduce RSV disease in infants, but timing and access still determine who actually gets protected.
Safety context: why the pregnancy window is narrow
CDC’s pregnancy guidance is tied to safety monitoring as well as effectiveness. In pre-licensure studies, there was an observed increase in preterm births, though it was not statistically significant; the recommended 32-to-36-week window was set to avoid vaccinating earlier in pregnancy, when a potential preterm-birth risk would matter more.
Since then, early post-licensure monitoring has been reassuring. CDC says preliminary findings from Vaccine Safety Datalink data did not find an increased risk of preterm birth or babies being born small for gestational age when vaccination happened during the recommended window. But CDC also says additional studies are ongoing, so this is still monitored evidence rather than the final word.
What newer studies suggest
An interim safety study in U.S. health plans found no clear safety signal in the outcomes it tracked during pregnancy after RSVpreF vaccination. That kind of observational research is helpful for real-world surveillance, but it cannot prove cause and effect the way a randomized trial can.
A separate multicenter case-control study found maternal RSV immunization was effective in preventing RSV-associated hospitalization in infants under 6 months. That adds support for the approach, while still leaving open practical questions about timing, season, and who benefits most from maternal vaccination versus infant antibody protection.
What readers can do now
If you are pregnant, the practical next step is to talk with your prenatal clinician now, especially if you are in the 32-to-36-week window or approaching your expected delivery date. The best option depends on gestational age, the season, and whether the baby is likely to be born soon enough to benefit from maternal vaccination.
If the pregnancy is already past the recommended window, the focus shifts to infant protection after birth. If the timing is uncertain, a clinician can help decide which strategy is most useful for your family.
Sources
Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.
This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.
